M

Monopar Therapeutics
D

MNPR

19.690
USD
0.19
(0.97%)
Market Open
Volume
734
EPS
-1
Div Yield
-
P/E
-10
Market Cap
103,919,803
News

Title: Monopar Therapeutics Inc

Sector: Healthcare
Industry: Biotechnology
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists ofValidiveforthe prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.